Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04999969 2026-02-03

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Phase 2 Active not recruiting

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03459846 2026-01-30

BAYOU

Phase 2 Active not recruiting

154 enrolled 13 charts

Genitourinary

Urinary Bladder Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

NCT03298451 2026-01-14

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Gynecologic

Endometrial Neoplasms

NCT04745689 2025-12-10

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Thoracic

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3 Active not recruiting

328 enrolled 23 charts

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 2 FDA

Thoracic

Small Cell Lung Carcinoma

NCT03842228 2025-10-14

COD

Phase 1 Active not recruiting

39 enrolled 15 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT05061134 2025-07-31

MONETTE

Phase 2 Active not recruiting

194 enrolled 21 charts

Dermatologic

Melanoma

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Phase 2 Active not recruiting

18 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

NCT03215095 2025-07-17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Phase EARLY_PHASE1 Active not recruiting

11 enrolled 6 charts

Head & Neck

Thyroid Neoplasms

NCT03837899 2024-10-29

Durvalumab and Tremelimumab for Pediatric Malignancies

Phase 1/2 Active not recruiting

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms